A clinical trial update was logged on September 4, 2026, for study NCT07481981, titled "A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)." The study is registered as Phase 3 and its current status is recruiting, according to the ClinicalTrials.gov listing.
This update is being tracked in connection with nesiritide, which carries an unapproved research status. No efficacy or safety results have been posted for this trial at this time. The listing confirms only the trial's phase, title, and recruiting status as of the date given, with no additional outcome data available for reporting.
Readers should note that a recruiting status indicates the trial is actively enrolling participants, not that any conclusions about the study drug have been reached. No dosing details, participant numbers, or endpoint data were included in the available event information, so none are reported here.
For more background on nesiritide, including its current regulatory classification and general context, see the compound overview.